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The potential role of nitric oxide synthase-2 (NOS2) in acute lung
injury (ALI) has gained increasing attention. This study evaluates
the effects of hypoxia, an important feature of ALI, on NOS2 expres-
sion in a rat model of ALI caused by exposure to hypoxia and LPS.
Exposure to hypoxia alone had no effect on the expression of NOS2
in rat lungs. LPS treatment resulted in a significant increase in NOS2
in the lungs, which was further enhanced by concomitant exposure
to hypoxia. Immunohistochemical analysis and in situ hybridization
showed no changes in the expression of NOS2 in lung resident cells
under any conditions. The increase in NOS2 levels is mainly due to
the influx of NOS2-expressing inflammatory cells. By morphologic
analysis, these inflammatory cells were identified as neutrophils,
lymphocytes, and monocytes. In vitro experiments of lung epithelial
and endothelial cell lines showed no detectable expression of NOS2
with any of the treatments. In a macrophage cell line, LPS-induced
NOS2 expression was not affected by the concomitant exposure to
hypoxia. In conclusion, LPS increases NOS2 expression in rat lungs
through the recruitment of NOS2-producing leukocytes. Simultane-
ous exposure to LPS and hypoxia results in a greater influx of inflam-
matory cells that further enhances NOS2 expression.
Keywords: acute respiratory distress syndrome; endotoxin; leukocytes;
sepsis
Nitric oxide (·NO) is a multifunctional, short-lived gas that
may contribute to toxic free radical production and potentiate
lung injury. ·NO is synthesized by a family of enzymes called
nitric oxide synthases (NOS). There are three NOS isoforms,
namely, NOS1 (neuronal NOS), NOS2 (inducible NOS), and
NOS3 (endothelial NOS). These isoenzymes were first puri-
fied from rat brain (1), murine macrophages (2), and bovine
aortic endothelial cells (3), respectively. NOS enzymes are
classically classified as either constitutive (NOS1 and NOS3)
or inducible (NOS2), although it is now known that the ex-
pression of NOS1 and NOS3 can be induced (4), and that
NOS2 is constitutively expressed in numerous cell types (5).
The so-called constitutive isoforms (NOS1 and NOS3) re-
lease low amounts of ·NO and their activity is dependent on
calcium and calmodulin (6). On the other hand, NOS2 pro-
duces large amounts of ·NO after induction by stimuli such
as endotoxin and inflammatory cytokines (7–9). All three iso-
enzymes have been found in the lung (10–12) and mediate a
wide variety of biological events in the respiratory system,
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such as bronchodilation (13, 14), pulmonary vasodilation (15,
16), and cytotoxicity (17).
Acute respiratory distress syndrome (ARDS), the most
severe manifestation of acute lung injury (ALI), is clinically
characterized by severe hypoxemia, diffuse pulmonary infil-
trates, and increased pulmonary capillary permeability (18).
Although significant advances have been achieved in the treat-
ment of ARDS, the mortality associated with this syndrome
still exceeds 40% (19). ·NO administered by inhalation has
been shown to have beneficial physiologic effects in ARDS,
such as decreased pulmonary pressures and improved oxygen-
ation, although clinical trials have failed to show improvements
in survival (20). Paradoxically, endogenous ·NO produced
mainly by NOS2 is thought to have deleterious effects and
has been implicated in the pathophysiologic mechanisms of
ALI (21–25). It has been reported that hypoxia, the main
clinical consequence of ALI, has important effects on the
regulation of NOS2 via hypoxia response elements present
in the NOS2 gene promoter (26). To better understand the
potential role of ·NO in ALI, and the importance of hypoxia
as an added cofactor, we used a rat model of LPS-induced
ALI combined with exposure to normobaric hypoxia. These
in vivo studies were followed by in vitro experiments using
various rat lung cell lines treated with LPS and/or hypoxia.
The expression of NOS2 in these models was determined
by Northern blot, in situ hybridization, Western blot, and
immunohistochemical analyses. Some of the results of these
studies have been previously reported in the form of an
abstract (27).
METHODS
See the online data supplement for additional detail on the methods used.
Animals and Treatments
Female Fischer Harlan rats were treated with an intraperitoneal injec-
tion of saline or LPS (0.1 mg/kg Escherichia coli O111:B4, phenol
extract, L-2630; Sigma, St. Louis, MO) and immediately exposed to
one of the following two conditions: (1 ) normoxia: room air (21.8C
and relative humidity of 40%); or (2 ) normobaric hypoxia: rats were
placed in a Plexiglas chamber at barometric pressure, and gassed with a
mixture of 9% O2–91% N2 at a constant flow throughout the experiment
(22.1C and relative humidity of 50.2%). Rats were killed by cervical
dislocation after 3, 6, 12, or 24 hours of treatment.
Left lobes of lungs were fixed either in 10% formalin or 4% para-
formaldehyde and embedded in paraffin or Epon, respectively. Right
lobes were divided into two portions and frozen in liquid nitrogen for
protein and RNA analyses. The study protocol conforms to National
Institutes of Health guidelines.
Wet/Dry Weight Determinations
To confirm the presence of lung injury, six animals per group were
exposed to the different treatment combinations for 6 hours, after which
the lung wet-to-dry weight ratio was determined.
Cell Lines and Exposures
Normal rat lung epithelial cells (CCL-149; American Type Tissue Collec-
tion [ATCC], Manassas, VA), alveolar macrophages (CRL-2192; ATCC),
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and rat pulmonary microvascular endothelial cells (RPMVECs; kindly
donated by U. Ryan, Avant Immunotherapeutics, Needham, MA) were
used.
Cell cultures were exposed to 20% O2, 5% CO2, 75% N2 (normoxia),
or were placed in an incubation chamber (Billups-Rothenberg, Del
Mar, CA) and gassed with 1% O2, 5% CO2, 94% N2 (hypoxia). LPS
(100 ng/ml) was added to the cell culture medium just before initiating
exposure to normoxia or hypoxia. Cells were exposed to each treatment
for 0.5, 1, 3, 6, 12, or 24 hours. Total RNA or protein was extracted
immediately after each treatment.
Northern Blot
Northern blot was performed as previously described (28) with slight
modifications.
In Situ Hybridization
The protocol followed was similar to that applied by Garcı´a and cowork-
ers (29).
Antibodies
Polyclonal anti-NOS2 antiserum sc-650 (Santa Cruz Biotechnology, Santa
Cruz, CA) was selected from previous studies in which other antibodies
(i.e., N32020–050; Transduction Laboratories, Heidelberg, Germany)
were tested. Adsorption controls were performed. Type II pneumocytes
were detected with monoclonal antibody MNF116 recognizing cytokera-
tins 5, 6, 8, 17, and 19 (M 0821; Dako, High Wycombe, UK).
Western Blot
The Western blot procedure was performed as previously described (30)
with minor modifications.
Immunohistochemistry
Paraffin sections of lung tissue were microwave-pretreated for antigen
retrieval. Sections were revealed with the EnVision system (Dako). Ad-
sorption controls for NOS2 were performed. The expression of NOS2
and MNF116 was quantified with the assistance of computer-aided image
analysis (analySIS; Soft Imaging System, Munich, Germany).
After plastic removal, semithin sections were processed in the same
manner as paraffin sections.
Statistical Analysis
The most representative times of exposure (3–24 hours in the in vivo
model and 12 hours in the in vitro model) were chosen for statistical
analysis (n 3). Densitometric values were normalized to S9 (Northern
blot) and -actin (Western blot). For statistical analyses, a Kruskall–
Wallis test was applied; in those cases in which significant statistical
variations were found, groups were compared using a Mann–Whitney
U test with the Bonferroni adjustment (SPSS, Chicago, IL).
RESULTS
In Vivo Model
Assessment of lung permeability after various treatments. Rats
were treated with LPS or saline and exposed to either normoxia
or hypoxia for 6 hours. Histologic examination of slides from
rats of different groups revealed differences only in the number
of inflammatory cells migrating to the lung (data not shown).
Whereas lungs treated with normoxia plus saline and with hyp-
oxia plus saline showed only scattered resident macrophages
and inflammatory cells, a considerable increase in the number
of inflammatory cells was observed in lungs treated with nor-
moxia plus LPS. The number of inflammatory cells was further
augmented in LPS-treated rats concomitantly exposed to hyp-
oxia. Because no other morphologic differences such as alveolar
wall thickening or edema were histologically evident, lung injury
was quantified by assessment of changes in vascular permeability.
The wet-to-dry lung weight ratios for each group were mea-
sured after 6 hours of treatment. Only the hypoxia plus LPS lung
group (4.79 0.3, n 6) showed a significantly greater ratio than
Figure 1. Changes in lung wet/
dry weight ratios after 6 hours
of treatment. Values are ex-
pressed as means (columns) 
SD (error bars) (n  6 for
each group). *p  0.05 com-
pared with normoxia plus sa-
line group.
the normoxia plus saline group (4.18  0.40, n  6, p  0.006).
The wet-to-dry lung weight ratios of rats treated with hypoxia
or LPS alone were similar to those of normoxic control lungs
(Figure 1).
NOS2 mRNA levels in rat lungs after hypoxia and/or LPS
exposure. Northern analysis of NOS2 mRNA expression in rats
treated with saline and exposed to normoxia or hypoxia revealed
a similarly weak but consistent 4.1-kb band (Figure 2), indicating
that acute normobaric hypoxia alone did not induce NOS2 gene
expression. In contrast, in lungs from rats treated with LPS and
exposed to normoxia there was a significant increase in the expres-
sion of NOS2 mRNA. This expression peaked at 3 hours and
began to decline after 6 hours of treatment, reaching control
values after 24 hours of exposure. When LPS-treated rats were
simultaneously exposed to hypoxia, NOS2 mRNA expression was
even greater than in rats treated with LPS and exposed to nor-
moxia (Figure 2). The survival rates of rats treated with hypoxia
plus LPS for 12 and 24 hours were 80 and 0%, respectively.
Figure 2. Northern blot analysis of nitric oxide synthase (NOS-2) messen-
ger RNA (mRNA) in rat lungs. (A ) Quantitation of NOS2 mRNA levels
normalized to the signal for S9 mRNA. To standardize between experi-
ments, an arbitrary density of one was assigned to the band obtained
from lungs of rats exposed to normoxia plus saline. Values are expressed
as means (columns)  SD (error bars) (n  4 for each group at each
time point). *p  0.05 compared with normoxia plus saline group. (B )
Representative Northern blot analysis of NOS2 and S9 mRNA from lung
extracts of rats exposed to normoxia (20% O2) or hypoxia (9% O2) and
injected with saline or LPS (0.1 mg/kg) for 3, 6, 12, and 24 hours.
Combined treatment of hypoxia and LPS was lethal at 24 hours of expo-
sure. Fifteen micrograms of total RNA were loaded per lane.
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In situ hybridization for NOS2 mRNA in lung sections from
animals treated with saline and normoxia or hypoxia showed
barely any labeling, whereas several cell types presented positive
staining in the lungs of rats treated with LPS and exposed to
either normoxia or hypoxia (Figure 3; only control and hypoxia
plus LPS lungs are shown). These cells appeared to be consistent
with inflammatory cells adhering to vascular endothelial cells
and with cells that have migrated into the lung parenchyma.
Labeling was absent when the hybridization was performed with
the sense riboprobe (Figures 3E and 3F).
NOS2 protein expression. Western blot analysis of NOS2 pro-
tein expression was performed on the same lungs used for North-
ern blot analysis. NOS2 protein was not detectable in lungs of
animals treated with saline and exposed to normoxia or hypoxia
(Figure 4). Treatment with LPS caused a significant increase in
the amount of NOS2 protein in the lungs of animals exposed to
normoxia or hypoxia, although the expression was greater in the
hypoxia plus LPS group. In the latter two groups, the induction of
NOS2 protein levels followed the same pattern observed for
NOS2 mRNA, with an approximate 3-hour delay (Figures 2
and 4). Parallel blots incubated with the anti-NOS2 antibody
preadsorbed with the sc-650 peptide showed no immunoreactive
band (data not shown).
In an attempt to determine the cell types in which NOS2
expression was increased, immunohistochemical localization of
NOS2 was performed in rats subjected to the aforementioned
treatments (Figure 5). Weak immunoreactivity for NOS2 in the
normoxia plus saline group was present in bronchiolar and vascu-
lar smooth muscle, bronchiolar epithelium, and Clara cells. No
immunostaining for NOS2 was detected in alveolar walls, endo-
thelial cells, or inflammatory cells related to blood vessels (Fig-
ures 5A–5C). Acute hypoxia alone had no detectable effect on
the pattern of expression of NOS2 as compared with control
Figure 3. In situ hybridization for NOS2 mRNA in rat lungs after 3 hours
of treatment. (A and B ) In situ hybridization performed with the antisense
riboprobe in normoxia plus saline-treated rat lungs. No detectable NOS2
mRNA is found in the lung parenchyma (A ) or in blood vessels (B ). In
hypoxia plus LPS-treated lungs, in situ hybridization with the antisense
riboprobe shows abundant positive cells within the parenchyma (C ), as
well as numerous positive cells within blood vessels, most of which ad-
hered to the endothelium (D ). Note the absence of labeling in the lung
parenchyma (E ) and in cells related to blood vessels (F ) when using the
sense riboprobe on hypoxia plus LPS-treated lungs. Original magnifica-
tion: (A, D, E, and F ) 360; (B and C ) 180.
Figure 4. Western im-
munoblot of lung NOS2
expression. (A) Densito-
metric analysis of NOS2
protein expression with
various treatments and
times of exposure is
shown as the ratio be-
tween NOS2 and -actin
optical densities at each
point. Because no de-
tectable bands were
found in the control (nor-
moxia plus saline) group,
an arbitrary density of
one was assigned to the band corresponding to the 3-hour normoxia
plus LPS group. Data shown represent means (columns)  SD (error
bars) (n4 for each group at each time point). *p0.05 compared with
normoxia plus saline group. (B ) Representative Western immunoblot of
lung NOS2 and -actin protein content of normoxic and hypoxic rats
injected with saline or LPS (0.1 mg/kg) for 3, 6, 12, and 24 hours.
Hypoxia plus LPS treatment for 24 hours was lethal. NOS2 antibody
detected a single immunoreactive band with an estimated molecular
mass of 130 kD.
animals (Figures 5D–5F). NOS2 immunostaining was greatly
increased in lungs of animals treated with LPS and exposed to
either normoxia (Figures 5G–5I) or hypoxia (Figures 5J–5L),
being more prominent and statistically significant (p  0.001)
in the latter. Immunohistochemical quantification of NOS2 ex-
pression by image analysis (Figure 6), corroborates the results
from Western blot analyses. Maximal NOS2 protein expression
occurred after 6 hours of treatment. The increased NOS2 immu-
nostaining was found in many inflammatory cells adhered to
vascular endothelial cells and in cells that appeared to have
migrated into the lung parenchyma.
Immunohistochemical staining for NOS2 on semithin sections
and serial consecutive sections, observed by electron microscopy
(Figure 7), identified NOS2-immunoreactive cells in the microvas-
culature of the lung predominantly as lymphocytes and neutro-
phils. Neutrophils were recognized by the multilobulated nucleus
and the presence of larger primary granules and specific granules
(Figures 7C–7E). Mononucleated cells also showed immunoreac-
tivity for NOS2 (Figures 7F and 7G). Because of the presence of
an indented nucleus and relatively condensed chromatin, few
primary granules, and a large number of free ribosomes in the
cytoplasm, these cells probably correspond to lymphocytes. The
size of these cells is that of medium-sized lymphocytes (about
7 m in diameter). Furthermore, histologic examination of re-
verse-face hematoxylin- and eosin-stained sections serial to NOS2-
immunostained sections (Figures 8A and 8B), showed that NOS2
immunoreactivity in large blood vessels of the lung corresponds
to cells with histologic features of monocytes. In the lung paren-
chyma, a few cells other than leukocytes were also positive for
NOS2. By studying serial reverse-face pair slides, one immuno-
stained for NOS2 and the other for specific cytokeratins, these
cells were identified as Type II pneumocytes (Figures 8C and
8D). After quantitative evaluation by image analysis, the propor-
tion of Type II cells with NOS2 immunoreactivity was 1.5 
0.003 and 1.46  0.008% in normoxia plus LPS and hypoxia
plus LPS groups, respectively. The contribution of Type II pneu-
mocytes to total NOS2 staining was also low: 1.6  0.007% in
the normoxia plus LPS group, and 0.18 0.001% in the hypoxia
plus LPS group.
290 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 168 2003
Figure 5. Immunolocalization
of NOS2 in lungs of rats in-
jected with saline or LPS (0.1
mg/kg) and exposed to nor-
moxia (20% O2) or normo-
baric hypoxia (9% O2) for 6
hours. In normoxic lungs (A–
C ), no detectable immuno-
staining for NOS2 is found
either in the blood vessels (B )
or in the parenchyma (C ). The
same results are observed in
rat lungs exposed to hypoxia
(D–F ). In LPS-treated lungs,
NOS2 immunoreactivity is ob-
served in inflammatory cells
mainly adhered to blood ves-
sels (H, arrowheads), and in
some cells of the lung paren-
chyma (I, arrows). Hypoxia plus
LPS treatment (J–L) dramati-
cally increases the number of
NOS2-immunoreactive cells (as
can be observed by comparing
G and J). In the latter group,
immunoreactivity is localized to
inflammatory cells in blood ves-
sels (K, arrowheads), and the
lung parenchyma (L, arrows).
Original magnification: (A, D,
G, and J) 90; (B, C, E, F, H, I,
K, and L) 300.
In conclusion, the greater expression of NOS2 protein in
lungs of rats treated with LPS and exposed to hypoxia, as com-
pared with LPS-treated rats exposed to normoxia, is due to a
greater number of NOS2-immunoreactive inflammatory cells
present in the former (Figures 5, 7, and 8). The expression of
NOS2 protein in bronchiolar epithelial cells was not affected by
any of the treatments.
In Vitro Model
NOS2 mRNA levels in cell lines. Rat lung epithelial cells (CCL-
149), RPMVECs, and alveolar macrophages (CRL-2192) were
exposed to normoxia or hypoxia for 0.5, 1, 3, 6, 12, or 24 hours
and treated concomitantly with or without LPS. Northern blot
analysis of NOS2 mRNA levels in these cell lines revealed differ-
ent responses according to cell type. NOS2 mRNA was not
detectable in epithelial or endothelial cells after any of the treat-
ment combinations (data not shown). In the rat alveolar macro-
phage cell line (Figure 9), NOS2 mRNA was barely observed
in cells exposed to normoxia or hypoxia. However, treatment
with LPS and exposure to normoxia resulted in the induction
of NOS2 gene expression, which was already detected 30 minutes
after the onset of treatment and gradually increased up to 12
hours. In comparison with normoxia plus LPS treatment, exposing
LPS-treated cells to hypoxia resulted in significant lower NOS2
mRNA levels (p  0.004) (Figure 9).
Protein levels. To determine the effects of the four different
treatments on the expression of NOS2 protein in the lung cell
lines studied, Western blot techniques were applied to protein
homogenates. NOS2 protein was not detected in epithelial or
endothelial cells after any of the treatments (data not shown).
As seen in Figure 10, NOS2 protein levels were higher in rat
Figure 6. Quantitative ev-
aluation of NOS2 immu-
nohistochemical staining.
Staining is depicted as the
percentage of stained area
versus total tissue area.
Data shown represent
means (columns) SD (er-
ror bars) (n  4, 5 slides
per animal, and 10 fields
[200] per slide were ana-
lyzed for each group at
each time point).
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alveolar macrophages exposed to hypoxia as compared with
those exposed to normoxia. In addition, exposing cells to LPS
plus normoxia resulted in a strong induction of NOS2 protein
expression, which increased gradually, reaching maximal levels
at 24 hours of treatment. As compared with LPS alone, the
concomitant exposure to LPS plus hypoxia resulted in a some-
what lower induction of NOS2 protein, although no significant
differences were found after 12 hours of treatment. Maximal
NOS2 protein induction in the alveolar macrophage cell line
was delayed in relation to the increase in mRNA expression, as
was also previously observed in the in vivo model.
DISCUSSION
There are two main findings in this study. First, in an in vivo
rat model, the injection of LPS caused an increase in the produc-
tion of NOS2 in the lung, mainly due to an influx of NOS2-
producing leukocytes and not because of the upregulation of
NOS2 expression in lung resident cells. Second, when treatment
Figure 7. (A and B) Semithin section of rat lung exposed to hypoxia plus
LPS for 6 hours, immunostained for NOS2, and (C–G ) serial consecutive
ultrathin section of the boxed area in (A ). (A ) Panoramic semithin section
in which numerous NOS2-positive cells are observed. (B ) Detail of the
boxed area in (A ). Identity of NOS2-immunostained and ultrastructurally
observed cells is shown by the arrow (B and C ) and the arrowhead (B
and F ). Note that both cells are localized within blood vessels (C and F )
(e  endothelial cell). (D and E ) Higher magnification of the cell shown
by the arrow in (B ) and (C ). This cell presents characteristic features of
a neutrophil, such as the multilobulated nucleus (D ) and the presence
of larger primary granules (arrow in E ) and specific (secondary) granules
(arrowhead in E ). (G ) Ultrastructural detail of the cell shown by the
arrowhead in (B ) and (F ), probably corresponding to a lymphocyte. The
cytoplasm is occupied by a multitude of free polyribosomes and a few
profiles of granular endoplasmic reticulum. A small amount of primary
granules is also observed (triangles). Original magnification: (A ) 190;
(B ) 380; (C and F ) 2400; (D ) 11300; (E ) 22600; (G ) 9000.
with LPS was combined with exposure to acute normobaric hyp-
oxia, there was an even greater migration of NOS2-expressing
leukocytes, which further increased the expression of NOS2
mRNA and protein levels in whole lung tissue; furthermore,
no induction or upregulation of NOS2 expression in any lung
resident cell type occurred.
Acute lung injury is defined as acute and persistent lung
inflammation, and is characterized clinically by hypoxemia, pul-
monary edema secondary to nonhydrostatic capillary permeabil-
ity, and diffuse pulmonary infiltrates on chest radiographs (31).
Acute respiratory distress syndrome (ARDS) refers to the most
severe end of the spectrum of ALI. The pathogenic mechanisms
of this disease are not well understood, but the role of reactive
oxygen species and ·NO has gained increasing attention. Previous
studies show that NOS2 expression and ·NO end products are
increased in lungs of patients with ARDS (25, 32). Whether ·NO
has a beneficial role or participates in the mechanisms of injury
is still debated (24). Several investigations suggest that NOS2
plays a harmful role in ALI, because released ·NO causes tissue
damage through reactions with reactive oxygen species, such as
superoxide, resulting in the formation of peroxynitrite (33, 34).
Kristof and colleagues showed that NOS2 knockout mice were
more resistant to LPS-induced lung injury than were wild-type
mice (23). Moreover, treatment with NOS2 inhibitors seems to
prevent ALI in sheep after burn and smoke inhalation injury
(35, 36). On the other hand, there are reports suggesting a bene-
ficial role of ·NO in ALI based on the following: (1) it downregu-
lates the expression of adhesion molecules, resulting in a reduc-
tion in the migration and accumulation of neutrophils (37); (2)
it inhibits cytokine production (38); and (3) in a clinical trial,
as had been previously shown for some animal models (39), the
use of NOS inhibitors in patients with sepsis resulted in an
increase in mortality (40). As suggested by Yang and colleagues
(41), the detrimental or beneficial role of ·NO in inflammatory
diseases might depend on the oxidant–antioxidant balance and
the severity of oxidative stress. Most investigations do agree that
in ALI there is an increased expression of NOS2 in the lungs.
However, most studies have used techniques such as Northern
blot and Western blot analyses of whole lung tissue, which are
not capable of determining the cell types responsible for the
NOS2 overexpression. The novelty of the work presented herein
is the use of parallel molecular and in situ techniques (in situ
hybridization and immunohistochemistry), which have led to the
identification of systemic inflammatory cells as the source of the
increased NOS2 levels in the lungs of normoxia plus LPS-treated
rats and hypoxia plus LPS-treated rats. Besides, immunohisto-
chemical and electron microscopy techniques show that the in-
creased NOS2 expression in the lungs is due to the presence of
monocytes in large blood vessels and neutrophils and lympho-
cytes in the microvasculature. In addition, no upregulation of
NOS2 expression in pulmonary resident cells occurs. Our experi-
ments with in vitro cell models confirm that in response to LPS
or hypoxia plus LPS, pulmonary epithelial and microvascular
endothelial cells do not express detectable NOS2, whereas in a
macrophage cell line the induction of the enzyme is evident
under both experimental conditions.
LPS administration was chosen for the present study because
of the widely used animal model of LPS-induced ALI (42, 43)
and the well known mechanisms by which LPS induces NOS2
and causes inflammation (44–47). In comparison with other LPS-
induced ARDS models, lower doses of LPS were chosen in our
study (0.1 mg/kg) to allow the combination of LPS and hypoxia.
Injection of LPS in experimental animals elicits a potent infiltra-
tion of neutrophils and lymphocytes in the lung, beginning in
the induction phase (up to 4 hours after LPS injection) and
maintained in the acute phase of the process (from 6 to 12 hours)
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Figure 8. Serial reverse-face
sections of rat lungs treated
with hypoxia plus LPS for 6
hours, and stained with hema-
toxylin and eosin and for NOS2
(A and B), and for cytokeratins
(MNF116 antibody) and NOS2
(C and D). Note that NOS2-
positive cells shown by arrows
in (B ) present histologic fea-
tures of monocytes in (A).
NOS2-immunoreactive cells,
shown by arrowheads in (B),
present histologic characteris-
tics of neutrophils in (A). (C)
Panoramic view of immuno-
staining with MNF116 (used as
a marker of Type II pneumo-
cytes in the lung parenchyma).
(D ) Serial reverse section
to (C ) immunostained for
NOS2. Note that few Type II
pneumocytes are immunore-
active for NOS2 (arrow in C
and D ). Original magnifica-
tion: (A and B )1200; (C and
D ) 500.
(9, 48, 49). In the recovery phase (12 to 48 hours), the number
of neutrophils decreases, being substituted by monocytes and
macrophages. This may explain why in this experimental model
NOS2-immunoreactive monocytes are found in large blood ves-
sels, whereas neutrophils and lymphocytes are found in the mi-
crovasculature. A similar pattern of inflammatory cell response
was found in response to LPS instilled intratracheally (50). Previ-
ous studies have also reported an increase in the number of
Figure 9. Northern blot analysis of NOS2 mRNA ex-
pression in the CRL-2192 macrophage cell line. (A )
Optical density of NOS2 mRNA after 12 hours of treat-
ment, expressed as the ratio of NOS2 and S9 mRNA.
To standardize between experiments, an arbitrary den-
sity of one was assigned to the band obtained from
cells exposed to normoxia (control group; zero time
point). Values are expressed as means (columns) SD
(error bars) (n  3 for each group). *p  0.05 com-
pared with control group. (B ) Northern blot analysis
of a representative experiment using the rat alveolar
macrophage cell line CRL-2192 cultured under nor-
moxic (20% O2) or hypoxic (1% O2) conditions and
treated with or without LPS (100 ng/ml) for the indi-
cated times (in hours). Fifteen micrograms of total RNA
were loaded per lane.
NOS2-expressing inflammatory cells in the lung parenchyma
(8, 51). Using immunohistochemical techniques, Buttery and
colleagues suggest that the induction of NOS2 after the injection
of LPS in rodents occurs predominantly in macrophages present
in many organs, including the lungs (8). By reciprocal bone
marrow transplantation between NOS2	/	 and NOS2
/
 mice,
and determining NOS2 activity in the lung, Wang and colleagues
suggest that both parenchymal and inflammatory cells contribute
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Figure 10. Western blot analysis of NOS2 in rat alveolar macrophage
cell line CRL-2192. (A ) Relative NOS2 protein levels after 12 hours of
treatment, determined by normalization to the correspondent -actin
optical density, are shown as means (columns)  SD (error bars) (n 
3 for each group). *p  0.05 compared with control group. There is
no significant difference between expression within hypoxia, LPS, and
hypoxia plus LPS treatments. To standardize between experiments, an
arbitrary density of one was assigned to the band obtained from cells
exposed to normoxia. (B ) Representative Western blot analysis of NOS2
and -actin protein content of rat alveolar macrophage cell line CRL-
2192, exposed either to normoxia or hypoxia and treated with or without
LPS (100 ng/ml) for the indicated times.
to the increased NOS2 production in lungs after the injection
of LPS (52). In a subsequent publication, the same group further
defines that the injury leading to microvascular leakage of pro-
teins is caused by NOS2 produced by bone marrow–derived
inflammatory cells (51). In the study presented herein, immuno-
histochemical and electron microscopy techniques show that the
cells responsible for the increased production of NOS2 after
LPS insult in lung tissue are monocytes, neutrophils, and lympho-
cytes. As previously reported (53–55), a few Type II pneumo-
cytes were also found to be immunoreactive for NOS2 after
LPS insult, although no clear upregulation of the enzyme was
observed in this cell type. Our in vitro experiments also failed
to show induction of NOS2 in alveolar epithelial cells and
RPMVECs in response to LPS. Other investigations have shown
induction of NOS2 in RPMVECs, although in response to tumor
necrosis factor- and interleukin-1 (56). This may suggest that
stimuli other than LPS are needed for NOS2 induction in this
cell line. As also reported for other macrophage cell lines (57),
the CRL-2192 cell line showed a high upregulation of NOS2
mRNA and protein after LPS administration. This induction
was higher than that obtained with the hypoxia or hypoxia plus
LPS treatments.
Hypoxemia and local tissue hypoxia are important patho-
physiologic consequences of ALI. A number of investigations
have reported that hypoxia transcriptionally upregulates NOS2
expression through hypoxia-inducible factor-1, which binds a
hypoxia response element in the promoter of the gene (58).
However, data from studies of NOS2 expression in animal mod-
els of hypoxia are controversial. There are reports of increased
(11, 58–60) and maintained (61–63) NOS2 lung expression in
response to low oxygen concentrations. In our rat model, NOS2
expression in the lung was not altered by exposure to acute
hypoxia alone (Figures 2, 4, and 5), which is consistent with the
observation by Gess and colleagues (61). A number of groups
have studied in vitro models to assess the effect of hypoxia on
NOS2 production, also finding conflicting results in different cell
types. Whereas in bovine pulmonary artery endothelial cells
hypoxia induces NOS2 promoter activity (58), results presented
herein and by others (56) show that hypoxia has no effect on
RPMVECs. These differences could be explained by the pheno-
typic heterogeneity of endothelial cells obtained from different
pulmonary blood vessels or from different species (64–66). In
macrophages, prior studies have shown that hypoxia alone does
not induce NOS2 expression, and that reoxygenation (67, 68),
or the combination of hypoxia with other stimuli, such as LPS
or IFN- (69), is required for its induction. Our results show
that acute hypoxia alone is not capable of inducing NOS2 mRNA
expression in a cultured rat lung macrophage cell line (Figure 9);
however, at the protein level, an increase is observed after 12
hours of treatment (Figure 10). Yu and colleagues reported that
hypoxia-inducible factor-1 protein is upregulated in several cell
types of the lung (pulmonary arterial endothelial cells, smooth
muscle and bronchial epithelial cells, alveolar macrophages, and
RPMVECs) and in ferret lungs exposed to acute hypoxia, and
that this upregulation is dependent on the concentration of oxygen
and the duration of the exposure (70). These investigators could
not detect hypoxia-inducible factor-1 protein in lungs ventilated
with 7% O2. This could explain the lack of NOS2 induction in
our lung model, in which rats were exposed to 9% O2.
In our opinion, the main achievement of this work is the analy-
sis of the concomitant effect of two of the main factors involved
in ALI (i.e., LPS and hypoxia), both in vivo and in vitro. Although
LPS treatment itself is thought to induce hypoxemia (via lung
injury), the administration of LPS alone does not completely mimic
the pulmonary effects of endotoxin-associated ALI, as noted by a
National Heart, Lung, and Blood Institute working group on acute
lung injury (71). In fact, this working group suggests that two-
hit models might better reflect actual conditions present in pa-
tients with ALI (71). In this sense, the concomitant exposure to
hypoxia and LPS has allowed us to more effectively compare
the relative importance of both factors and their synergistic effect
in NOS2 induction. To expose animals to hypoxia and LPS
simultaneously without causing their death, lower doses of LPS
as compared to other LPS-based ALI models were used. As
seen in Figure 1, the combination of hypoxia and LPS in our
experimental conditions elicited a modest but statistically sig-
nificant increase in lung wet-to-dry ratio after 6 hours of treatment,
which suggests that our model may represent the early stages of
ALI. With this combination, hypoxia did cause an increase in the
LPS-dependent expression of NOS2 mRNA and protein in whole
lungs as observed by Northern and Western blot analyses (Figures
2 and 4). Again, by the parallel use of molecular and in situ
techniques (NOS2 mRNA hybridization and immunohistochemis-
try), this increase in NOS2 expression was observed to be due to
an even greater influx of leukocytes into the lung parenchyma
(Figures 3 and 5). Finally, by immunocytochemical and morpho-
logic analyses in serial sections, these NOS2-expressing inflamma-
tory cells were identified as monocytes, neutrophils, and lympho-
cytes (Figures 7 and 8). Studies report that neutrophils adhering
to the lung vasculature after LPS injection are activated cells
in which apoptosis is decreased (72). In endothelial cells, the
combination of hypoxic stress and LPS or cytokines increases the
expression of specific adhesion molecules such as intercellular
adhesion molecule-1 (73, 74) and E-selectin (75). In addition,
several studies have demonstrated that hypoxia increases leuko-
cyte adhesion to endothelial cells through the induction of inte-
grins on the surface of leukocytes (76, 77). Moreover, high bron-
choalveolar lavage levels of interleukin-6 have been found in
patients with ARDS (78), and interleukin-6 treatment in rabbits
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results in the release of less deformable polymorphonuclear leuko-
cytes, which are preferentially sequestered in lung microvessels
(79). Therefore, because of the interaction of adhesion molecules
in leukocytes and endothelial cells, we suggest that the velocity
of leukocyte rolling might be diminished under hypoxic conditions,
favoring the permanence of the inflammatory cells in the lung. It
is possible that by concomitant treatment with LPS and hypoxia,
not only is the recruitment of LPS-induced NOS2-producing in-
flammatory cells enhanced, but the time spent by these cells in
the pulmonary vasculature is prolonged, thus resulting in enhanced
expression of NOS2 in whole lung tissue as compared with LPS
administration alone. In fact, the synergistic effect of hypoxia and
LPS on the influx of NOS2-producing inflammatory cells to the
lung might have been underestimated in the pathogenesis of
ARDS. Furthermore, the severity of this syndrome might be medi-
ated by the inflammatory products released by leukocytes, rather
than by the intrinsic toxicity of ·NO, as has already been suggested
in various studies (25, 34).
As shown in the in vitro experiments, in no individual cell
lines used in this study did the concomitant exposure to hypoxia
plus LPS result in an increase in NOS2 production as compared
with LPS treatment alone. If anything, in the macrophage cell
line (CRL-2192) hypoxia attenuated the LPS-dependent increase
in NOS2 mRNA (Figure 9). Others have also shown in RPMVECs
that hypoxia attenuates LPS-dependent NOS2 upregulation (56).
This further suggests that the increased expression of NOS2 in
whole lung tissue after treatment with LPS and hypoxia is due to
the recruitment of a greater number of cells that express NOS2
(monocytes, neutrophils, and lymphocytes), and not because of
upregulated expression in pulmonary resident cells.
In conclusion, in a model of ALI that combines treatment
with LPS and exposure to hypoxia, NOS2 expression is increased
in the lung parenchyma due to an increase in the recruitment
of leukocytes expressing NOS2. Exposure to hypoxia enhances
the LPS-dependent influx of NOS2-expressing inflammatory
cells. Neither LPS nor hypoxia, alone or in combination, seems
to upregulate NOS2 expression in lung resident cells. In vitro
studies using epithelial, endothelial, and macrophage rat pulmo-
nary cell lines further corroborate these results.
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